Therapeutics

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

December 9, 2025

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve…

HHealth

Regular mammograms linked to longer survival in women over 80

December 5, 2025

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows…

HHealth

Scientists uncover how amino acids stabilize proteins in solution

November 27, 2025

The Global Virus Network (GVN), a coalition of leading human and animal virologists in more than 40 countries…

HHealth

Mapping the evolutionary trajectory of meningiomas at single-cell resolution

November 22, 2025

Researchers at Washington University School of Medicine in St. Louis, along with collaborators at Northwestern University, have developed…

HHealthcare

2 No-Brainer Healthcare Stocks to Buy Now

November 19, 2025

Pfizer’s acquisition of obesity drugmaker Metsera positions the pharmaceutical giant to compete in a market expected to reach…

HHealth

November 14, 2025

Glioblastoma-the most aggressive form of brain cancer-remains one of medicine’s biggest challenges. Despite surgery, radiotherapy, and chemotherapy, most…

HHealth

Novel treatment disrupts tumor immunosuppression in pancreatic cancer

November 13, 2025

Last year, researchers at the University of California, Riverside, developed a novel “molecular crowbar” strategy to degrade the oncogenic enzyme…

HHealth

Daily coffee linked to lower risk of irregular heart rhythm episode in AFib patients

November 11, 2025

Perhaps the most intriguing implication of recent breakthrough research lies in an unexpected connection: the most rigorous mechanistic…

HHealth

NYU Langone strengthens world-leading GI cancer program with renowned leaders

November 8, 2025

Researchers at the School of Dentistry at UT Health San Antonio, the academic health center of The University…

SScience

New imaging technique enhances live-cell visualization in standard lab setups

November 7, 2025

The enzyme RNA polymerase II transcribes genes into messenger RNA. This process is guided by modifications to the enzyme’s…

HHealth

Scripps Research professor wins $3.2 million grant to unravel the mysteries of type 1 diabetes

October 29, 2025

Luc Teyton, professor in the Department of Immunology and Microbiology at Scripps Research, has received a five-year, $3.2…

HHealthcare

Elevara Medicines Raises $70 Million Series A to Advance

October 22, 2025

Co-led by Forbion and Sofinnova Partners, along with founding investor Monograph Capital, and WeatherdenInnovative lead program, ELV001, in-licensed…

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer

Global Virus Network outlines priorities as Marburg virus emerges in Ethiopia

Intranasal nanomedicine shows promise against glioblastoma

2 No-Brainer Healthcare Stocks to Buy Now

New insights into glioblastoma survival linked to brain fluid dynamics

Collaborative effort advances next-generation therapies for pancreatic and GI cancers

The caffeine conundrum in rapid depression treatments

New NIH grants fuel research in oral cancer treatment and pain relief

Comprehensive kinase atlas reveals new insights into cell signaling and disease

Scripps Research professor wins $3.2 million grant to unravel the mysteries of type 1 diabetes

Elevara Medicines Raises $70 Million Series A to Advance